Crocs, Inc. Appoints Susan Healy as EVP and Chief Financial Officer for Crocs Inc.
Get Alerts CROX Hot Sheet
Join SI Premium – FREE
"On behalf of the Board, I would like to welcome Susan to Crocs, Inc. Following a comprehensive search, we are pleased to have hired an accomplished financial executive of Susan's caliber," said
"I am excited to be joining Crocs Inc. as the Chief Financial Officer" said
The Company reports its fiscal first quarter today,
About Crocs, Inc.:
Crocs, Inc. (Nasdaq: CROX), headquartered in
Forward Looking Statements
This press release includes statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
These include statements regarding future outlook, contributions of new executives, and expectations (financial or otherwise) and intentions. These statements involve known and unknown risks, uncertainties, and other factors, which may cause our actual results, performance, or achievements to be materially different from any future results, performances, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include factors described in our most recent Annual Report on Form 10-K under the heading "Risk Factors" and our subsequent filings with the Securities and Exchange Commission. Readers are encouraged to review that section and all other disclosures appearing in our filings with the Securities and Exchange Commission.
Category: Investors
Investor Contact: | ||
(303) 848-7005 | ||
PR Contact: | ||
(303) 848-7885 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/crocs-inc-appoints-susan-healy-as-evp-and-chief-financial-officer-for-crocs-inc-302137462.html
SOURCE Crocs, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ROC to acquire digital forensics firm ZTC for up to $3M
- Welcome to the Superaging Era: Youth is no Longer the Holy Grail as Gen X and Millennials Chase the 100-Year Lifestyle
- Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Goldman Sachs, Definitive Agreement, Erinn MurphySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share